Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.35USD
14 Dec 2017
Change (% chg)

$-0.14 (-2.55%)
Prev Close
$5.49
Open
$5.49
Day's High
$5.73
Day's Low
$5.25
Volume
68,730
Avg. Vol
152,711
52-wk High
$14.09
52-wk Low
$4.91

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $201.44
Shares Outstanding(Mil.): 36.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

Nov 09 2017

BRIEF-Nabriva Therapeutics announces pricing of public offering of ordinary shares of nearly $80 mln

* Nabriva Therapeutics announces pricing of public offering of ordinary shares of approximately $80 million

Sep 19 2017

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

Sep 18 2017

UPDATE 2-Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Sept 18 Nabriva Therapeutics Plc shares nearly doubled in morning trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.

Sep 18 2017

Nabriva's pneumonia drug meets main goal in late-stage study

Sept 18 Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading.

Sep 18 2017

BRIEF-Nabriva therapeutics announces positive topline results

* Nabriva Therapeutics announces positive topline results from global, phase 3 clinical trial evaluating IV and oral lefamulin for the treatment of community-acquired bacterial pneumonia

Sep 18 2017

BRIEF-Nabriva Therapeutics reports Q2 loss per share $0.54

* Nabriva Therapeutics reports second quarter 2017 financial results and recent corporate highlights

Aug 07 2017

BRIEF-Nabriva Therapeutics files for mixed shelf of upto $175 mln - SEC Filing

* Files for mixed shelf of upto $175 million - SEC Filing Source text: [http://bit.ly/2v5i1V5] Further company coverage:

Jul 28 2017

BRIEF-Nabriva Therapeutics appoints new board members

* Nabriva Therapeutics appoints Carrie Bourdow and Colin Broom to the board Source text for Eikon: Further company coverage:

Jun 26 2017

Earnings vs. Estimates